Your browser doesn't support javascript.
loading
PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents.
Byrne, Julianne; Grabow, Desiree; Campbell, Helen; O'Brien, Kylie; Bielack, Stefan; Am Zehnhoff-Dinnesen, Antoinette; Calaminus, Gabriele; Kremer, Leontien; Langer, Thorsten; van den Heuvel-Eibrink, Marry M; van Dulmen-den Broeder, Eline; Baust, Katja; Bautz, Andrea; Beck, Jörn D; Berger, Claire; Binder, Harald; Borgmann-Staudt, Anja; Broer, Linda; Cario, Holger; Casagranda, Leonie; Clemens, Eva; Deuster, Dirk; de Vries, Andrica; Dirksen, Uta; Winther, Jeanette Falck; Fosså, Sophie; Font-Gonzalez, Anna; Grandage, Victoria; Haupt, Riccardo; Hecker-Nolting, Stefanie; Hjorth, Lars; Kaiser, Melanie; Kenborg, Line; Kepak, Tomas; Kepáková, Katerina; Knudsen, Lisbeth E; Krawczuk-Rybak, Maryna; Kruseova, Jarmila; Kuehni, Claudia E; Kunstreich, Marina; Kuonen, Rahel; Lackner, Herwig; Leiper, Alison; Loeffen, Erik A H; Luks, Ales; Modan-Moses, Dalit; Mulder, Renee; Parfitt, Ross; Paul, Norbert W; Ranft, Andreas.
Afiliación
  • Byrne J; Boyne Research Institute, 5 Bolton Square, East, Drogheda, Co. Louth A92 RY6K, Ireland. Electronic address: jbyrne@boyneresearch.ie.
  • Grabow D; German Childhood Cancer Registry (GCCR), Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Mainz, Germany.
  • Campbell H; Boyne Research Institute, 5 Bolton Square, East, Drogheda, Co. Louth A92 RY6K, Ireland.
  • O'Brien K; Pintail Ltd, Dublin, Ireland.
  • Bielack S; Department of Paediatrics &- Oncology, Hematology and Immunology, Centre for Paediatric, Adolescent and Women's Medicine, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.
  • Am Zehnhoff-Dinnesen A; Department for Phoniatrics and Pedaudiology, Universitätsklinikum, Münster, Germany.
  • Calaminus G; Department of Paediatric Haematology and Oncology Universitätsklinikum, Bonn, Germany.
  • Kremer L; Department Pediatric Oncology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, The Netherlands; Prinses Máxima Center for Paediatric Oncology, Utrecht, The Netherlands.
  • Langer T; Paediatric Oncology and Hematology, University Hospital for Children and Adolescents, University zu Lübeck, Lübeck, Germany.
  • van den Heuvel-Eibrink MM; Prinses Máxima Center for Paediatric Oncology, Utrecht, The Netherlands; Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
  • van Dulmen-den Broeder E; Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatrics, Cancer Centre Amsterdam, Amsterdam, The Netherlands.
  • Baust K; Department of Paediatric Haematology and Oncology Universitätsklinikum, Bonn, Germany.
  • Bautz A; Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Beck JD; Klinik für Kinder und Jugendliche, Friedrich-Alexander- Universität, Erlangen, Nürnberg, Germany.
  • Berger C; Department of Paediatric Hematology and Oncology Unit, University Hospital of Saint-Étienne, Saint-Étienne, France; Epidemiology of Childhood and Adolescent Cancers, CRESS, INSERM, UMR 1153, Paris Descartes University, Villejuif, France.
  • Binder H; Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
  • Borgmann-Staudt A; Charité - Universitätsmedizin, Berlin, Germany.
  • Broer L; Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Cario H; Department of Paediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.
  • Casagranda L; Department of Paediatric Hematology and Oncology Unit, University Hospital of Saint-Étienne, Saint-Étienne, France.
  • Clemens E; Prinses Máxima Center for Paediatric Oncology, Utrecht, The Netherlands; Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Deuster D; Department for Phoniatrics and Pedaudiology, Universitätsklinikum, Münster, Germany.
  • de Vries A; Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Dirksen U; Pediatrics III, Pediatric Hematology and Oncology, West German Cancer Centre, University Hospital, Essen, Germany.
  • Winther JF; Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
  • Fosså S; Institutt for Klinisk Medisin, Universitetet I Oslo, Oslo, Norway.
  • Font-Gonzalez A; Department Pediatric Oncology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, The Netherlands.
  • Grandage V; University College London Hospital, London, UK.
  • Haupt R; Epidemiology and Biostatistics Unit and Italian Off-Therapy Registry (OTR), Istituto Giannina Gaslini, Via Gerolamo Gaslini, 5, 16148, Genova, Italy.
  • Hecker-Nolting S; Department of Paediatrics &- Oncology, Hematology and Immunology, Centre for Paediatric, Adolescent and Women's Medicine, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.
  • Hjorth L; Department of Paediatrics, Lund University, Skåne University Hospital, Lund, Sweden.
  • Kaiser M; German Childhood Cancer Registry (GCCR), Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Mainz, Germany.
  • Kenborg L; Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Kepak T; University Hospital Brno, Brno, Czech Republic; International Clinical Research Center (FNUSA-ICRC), Brno, Czech Republic.
  • Kepáková K; University Hospital Brno, Brno, Czech Republic.
  • Knudsen LE; Institute of Public Health, University of Copenhagen, Copenhagen, Denmark.
  • Krawczuk-Rybak M; Medical University of Bialystok, Bialystok, Poland.
  • Kruseova J; Motol Teaching Hospital, Prague, Czech Republic.
  • Kuehni CE; Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  • Kunstreich M; Department of Paediatric Oncology, Haematology and Immunology, Medical Faculty, Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany.
  • Kuonen R; Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  • Lackner H; Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.
  • Leiper A; Great Ormond Street Children's Hospital, London, UK.
  • Loeffen EAH; Department of Pediatric Oncology/Hematology, University of Groningen, Beatrix Children's Hospital, University Medical Center Groningen, Groningen, the Netherlands.
  • Luks A; Motol Teaching Hospital, Prague, Czech Republic.
  • Modan-Moses D; Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel Hashomer, Israel; The Sakler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Mulder R; Department Pediatric Oncology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, The Netherlands.
  • Parfitt R; Department for Phoniatrics and Pedaudiology, Universitätsklinikum, Münster, Germany.
  • Paul NW; Institute for the History, Philosophy, and Ethics of Medicine, Johannes Gutenberg University Center Mainz, Mainz, Germany.
  • Ranft A; Pediatrics III, Pediatric Hematology and Oncology, West German Cancer Centre, University Hospital, Essen, Germany.
Eur J Cancer ; 103: 227-237, 2018 11.
Article en En | MEDLINE | ID: mdl-30273888
ABSTRACT

AIMS:

Survival after cancer diagnosed during childhood or adolescence continues to improve with new treatments and supportive therapies. Optimal long-term care requires that risks to vulnerable organs are clearly defined and translated into guidelines that are implemented into practice. PanCareLIFE is a pan-European consortium that addresses survivorship issues comprising fertility, hearing impairment and quality of life. This article describes the scientific basis of PanCareLIFE's studies.

METHODS:

PanCareLIFE involves 17 partner institutions from eight European countries, with additional 11 data providers from five other countries. Study designs and methods include molecular genetic, cohort and case-control studies, a longitudinal study and an intervention study. Ethics and data protection issues have been taken into account from the beginning.

RESULTS:

PanCareLIFE will investigate the way that treatment impairs female fertility, by evaluating anti-Müllerian hormone levels and the underlying genetic susceptibility to loss of fertility. For our fertility studies, more than 6000 survivors have completed questionnaires, more than 1500 provided serum samples and more than 400 case-control triads have been identified. Fertility preservation guidelines for boys and girls will be developed. More than 2000 survivors have contributed audiograms for the ototoxicity study. Almost 1000 samples were sent for genetic analysis related to ototoxicity and gonadal reserve. The SF-36 questionnaire will measure quality of life in more than 10,000 survivors.

CONCLUSIONS:

The large number of subjects enrolled in PanCareLIFE and the detailed information accumulated will allow in-depth evaluation of important outcomes. Fertility preservation guidelines will help patients and their families make informed decisions and contribute to their long-term well-being.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Calidad de Vida Tipo de estudio: Guideline / Observational_studies / Qualitative_research / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn País/Región como asunto: Europa Idioma: En Revista: Eur J Cancer Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Asunto principal: Calidad de Vida Tipo de estudio: Guideline / Observational_studies / Qualitative_research / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn País/Región como asunto: Europa Idioma: En Revista: Eur J Cancer Año: 2018 Tipo del documento: Article